Clinical trial
Evaluation of the Safety and Tolerability of Re-dosing With Intravenous (iv) Otelixizumab in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus
NCT01222078 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Evaluation of the Safety and Tolerability of Re-dosing With Intravenous (iv) Otelixizumab in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus
- Lead sponsor
- GlaxoSmithKline
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- November 22, 2010
- Completion date
- May 19, 2011
- Enrollment
- 1 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.